Agoracom

In the Dutton Report: "Specifically, we anticipate a $3 million milestone payment once Phase II studies of the Company’s lead compound are completed, and royalty and other income could approximate $500,000." Also regarding Phase II Timeline: ....Patient enrollment has taken somewhat longer than anticipated, but it is estimated that another 30 patients will be enrolled by the end of November, which would bring the total up to the targeted 210 patients. These are being treated in 14 centers for arthritis of the knee, each over a period of six weeks." In January some time they should release the results and we should see an uptick. How much lets not get greedy. They went to .25 when we found out about Proprius. Now that they have the total cost covered for all research and marketing they can just worry about hitting the milestones. I too think JM Dutton is just covering themselves since they called .35 and got blindsided by the large investors that dumped. Good Luck to all See you in January(bonus capital gain is on next years taxes)